Summary of Key Points Core Viewpoint - *ST Suwu (600200) is facing significant risks of forced delisting due to ongoing investigations by the China Securities Regulatory Commission (CSRC) and abnormal stock price fluctuations [1][3]. Trading Information - On May 16, *ST Suwu closed at 2.31 yuan, down 2.94%, with a turnover rate of 13.22%, trading volume of 939,500 shares, and a transaction value of 216 million yuan [1]. - The fund flow on the same day showed a net inflow of 17.62 million yuan from institutional investors, while retail investors experienced net outflows of 10.56 million yuan and 7.06 million yuan respectively [1][3]. Company Announcements - The company announced that its stock price had deviated by more than 12% over three consecutive trading days, leading to an investigation by the CSRC [1][3]. - There is a risk of forced delisting if the CSRC's findings indicate major violations of regulations [1]. - The auditing firm, Zhongxing Caiguanghua, issued an audit report for the fiscal year 2024 with a disclaimer of opinion due to non-operational fund occupation by related parties [1]. - The chairman of the company is under investigation for alleged violations of information disclosure regulations [1].

Core Viewpoint - Jinzhou Port Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected information disclosure violations, which may lead to significant illegal delisting of its stock due to false records in financial reports from 2020 to 2023 [1][2][3] Group 1: Investigation and Potential Delisting - The company received a notice from the CSRC regarding administrative penalties and market entry bans, indicating that its annual reports from 2020 to 2023 contain false records [1][2] - The CSRC's previous decision on November 1, 2024, confirmed that the company's annual reports from 2018 to 2021 also contained false records, leading to the current investigation [1][2] - If the company is found to have committed significant illegal acts, its stock may be terminated from listing on the Shanghai Stock Exchange [2][3] Group 2: Financial and Regulatory Risks - As of May 9, 2025, the company's stock price has been below RMB 1 for four consecutive trading days, which could trigger delisting if it continues for 20 trading days [3] - The company's audited net assets for 2024 were negative, and the financial report received a disclaimer of opinion, which may lead to financial delisting risks [3][4] - The company has been flagged for regulatory delisting risks due to significant non-operating fund occupation and failure to correct issues within the specified timeframe [5][6]

*ST锦港公告，公司因涉嫌信息披露违规，被中国证监会立案调查。2025年4月29日，公司收到中国证 监会辽宁监管局《行政处罚及市场禁入事先告知书》，查明公司2022年年度报告、2023年年度报告及 2024年第一季度报告存在虚假记载。根据《事先告知书》《决定书》所认定的事实，公司2020年至2023 年年度报告连续4年存在虚假记载，可能被实施重大违法强制退市。 ...

Group 1 - The core point of the news is that *ST Oriental (600811.SH) has been decided to be delisted by the Shanghai Stock Exchange due to serious financial misconduct, with the delisting date set for April 30, 2025 [1] - The company inflated its revenue by a total of 16.13 billion yuan and its costs by 16.073 billion yuan from 2020 to 2023, which accounted for 13.56% to 50.44% of its revenue during those periods [1] - The company has reported significant losses over the years, with net profits of -1.719 billion yuan, -996 million yuan, and -1.557 billion yuan from 2021 to 2023, totaling over 4.2 billion yuan in losses, and an expected loss of 800 million to 1.2 billion yuan in 2024 [1] Group 2 - On March 16, 2023, *ST Oriental was subjected to a major illegal forced delisting, leading to a continuous drop in stock prices after resumption of trading [2] - The chairman Zhang Hongwei was fined 10 million yuan and banned for life from the securities market, while seven other responsible individuals were fined a total of 29 million yuan [2] - As of September 30, 2022, nearly 130,000 shareholders were affected by the company's financial issues [2] Group 3 - Wu Xiaoqiu, a prominent figure in China's financial research, emphasized the need for *ST Oriental to serve as a cautionary case similar to the Enron scandal in the U.S., advocating for severe penalties against the company [4] - He called for the company to face extreme financial penalties and imprisonment for those responsible, highlighting the importance of accountability in the market [4]

Core Viewpoint - The Shenzhen Stock Exchange has decided to terminate the listing of ST Puli's stock and convertible bonds due to serious financial fraud issues, marking a significant change in the company's status in the capital market [4][5]. Financial Fraud and Consequences - ST Puli was found to have inflated its profits by a total of 669 million yuan, which accounted for 73.83% of the total reported profits for 2021 and 2022 [5][6]. - The company's core management, including the chairman and general manager, were involved in orchestrating the financial fraud, leading to severe penalties including a total fine of 24.2 million yuan and market bans for key executives [6][7]. Revenue Trends - In 2020, the company reported revenue of 1.189 billion yuan, a year-on-year increase of 25.10%, and a net profit of 407 million yuan, up 35.30% [6]. - Revenue continued to grow in 2021, reaching 1.509 billion yuan (up 26.94%), but net profit only slightly increased to 417 million yuan (up 2.25%) [6]. - In 2022, revenue rose to 1.619 billion yuan (up 7.31%), but net profit fell significantly to 295 million yuan, a decrease of 29.20% [6][7]. - By 2023, revenue dropped to 1.304 billion yuan, a decline of 19.43%, with net profit plummeting to 85.92 million yuan, down 70.87% [7]. Product Performance - The company's major products, particularly cardiovascular drugs, allergy medications, antibiotics, and digestive drugs, experienced significant revenue declines in 2023 [7]. - The overall business environment for ST Puli is deteriorating, with challenges expected to intensify in 2024, despite some products showing temporary growth [7]. Market Implications - The termination of ST Puli's listing serves as a warning to the pharmaceutical industry about the importance of compliance and maintaining core competitiveness to gain market trust [7].

星标 ★ IPO日报 精彩文章第一时间推送 4月18日晚间，海南普利制药股份有限公司（300630.SZ，以下简称"*ST普利"或"普利制药"）发布公告，公司于2025年4月18日收到深交 所《关于海南普利制药股份有限公司股票及可转换公司债券终止上市的决定》。深圳证券交易所决定终止公司股票及可转债上市。 公司股票及可转债进入退市整理期的起始日为2025年4月28日，退市整理期为十五个交易日，预计最后交易日期为2025年5月21日。 制图：佘诗婕 虚增利润近7亿 今年3月，上市公司发布公告称，收到证监会行政处罚决定书。 2021年至2022年，普利制药通过虚构成品药和原料药销售业务的方式，虚假确认药品销售收入和利润。 其中，2021年多计营业收入 436004495.01元，占当年披露营业收入的28.90%，对应营业成本128197101.98元，多计利润总额290175562.61元，占当年披露利润 总额的 62.06% ；2022年多计营业收入455776233.78元，占当年披露营业收入的25.23%，对应营业成本69013203.17元，多计利润总 额 379066467.07元，占当年披露利润总额的8 ...

| 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损:43,200 万元-53,700 万元 | 亏损:67,278 万元 | | 扣除非经常性损 益后的净利润 | 亏损:46,921 万元-57,421 万元 | 亏损:70.133 万元 | | 营业收入 | 72,500 万元一81,500 万元 | 55,679 万元 | | 扣除后营业收入 | 71,500 万元-80,500 万元 | 54,380 万元 | 东方通称，2024年度公司持续推进市场拓展工作，同时降本增效初见成效，报告期亏损同比收窄约 20%-36%；若不考虑商誉减值计提因素，公司亏损收窄金额预计为1.74亿元至 2.09亿元，较上年同期亏 损收窄约60%-72%。 值得注意的是，2022年和2023年，东方通实现归属净利润分别约为-3936.65万元、-6.73亿元。 截至4月14日收盘，东方通报14.99元每股，收涨1.42%，总市值83.63亿元。 （文章来源：新华财经） 东方通称，若后续经中国证监会行政处罚认定的事实，触及《深圳证券交易所创业板股票上市规则 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed strict penalties on Hainan Puli Pharmaceutical Co., Ltd. for significant false reporting in its annual reports for 2021 and 2022, leading to a forced delisting process due to violations exceeding 50% of reported profits [3][5]. Group 1: Regulatory Actions - The CSRC announced administrative penalties against Puli Pharmaceutical for major false records in its annual reports, with a total profit inflation exceeding 500 million yuan over two years [3]. - The Shenzhen Stock Exchange has initiated the process for the termination of Puli's stock listing due to these violations [3][5]. - The company has issued 11 risk warning announcements since the initial notice of administrative penalties [5]. Group 2: Financial Misconduct - Puli Pharmaceutical inflated its revenue by 1.03 billion yuan, accounting for 31.08% of the total reported revenue over the two years [6]. - The inflated profit totaled 695 million yuan, representing 76.72% of the total reported profit for the same period [6]. - In 2021, the profit inflation was 308 million yuan, which was 65.88% of the reported profit for that year, while in 2022, it was 387 million yuan, making up 88.27% of the reported profit [6]. Group 3: Legal and Financial Implications - The CSRC has imposed a total fine of 24.2 million yuan on the company and six responsible individuals, with significant penalties including a 5 million yuan fine and a 10-year market ban for one individual [6]. - A lawsuit involving investors against Puli Pharmaceutical and its accounting firm is scheduled for April 9, 2024, with potential civil compensation for affected investors [6]. - The company currently has over 2 billion yuan in interest-bearing liabilities, facing increased repayment pressure following the delisting [7].

作 者丨杨坪 编 辑丨张伟贤 刘雪莹 刚 刚 ， 东 方 集 团 发 布 风 险 提 示 公 告 ， 今 日 （ 3 月 1 2 日 ） 公 司 股 价 盘 中 大 幅 上 涨 ， 股 价 波 动 较 大 。 公 司 预 计 将 触 及 重 大 违 法 强 制 退 市 情 形 ， 存 在 不 符 合 重 整 条 件 的 风 险 ， 敬请广大投资者理性投资，并注意投资风险。 二级市场上，东方集团1 2日以跌停价开盘，突然被涌入的买盘瞬间拉升至涨停板， 走出"地天 板"， 超1 0 0多万手买单封在涨停板。 此前，在连续四年重大财务造假被证监会通报后，东方 集团已连续7个交易日的一字跌停。 3 月 1 2 日 早 盘，A 股 震 荡 调 整，三 大 指 数 涨 跌 不 一 。 沪 深 两 市 半 日 成 交 额 1 万 亿，较 上 个 交 易 日 放 量 7 9 0 亿 。 东方集团退市危机"始末" 根据中国证监会发布的阶段性调查进展情况，现已初步查明，东方集团披露的2 0 2 0年至2 0 2 3 年财务信息严重不实，涉嫌重大财务造假，可能触及重大违法强制退市情形。 亏损额或远超4 2亿元 提到东方集团，很多人 ...

重大退市风险面前突然来了一个涨停板！ 在东方集团连续跌了七个跌停板之后，今天早上亦一度跌停，并跌破1元/股，但随后股价快速拉升涨停，上演"地天 板"走势，截至上午收盘，成交额超8亿元。 然而就在此时，该股罕见地于中午发布风险提示公告称，预计将触及重大违法强制退市情形，请广大投资者理性投 资。与此同时，还表示，公司存在不符合重整条件的风险。 7个跌停之后突现地天板 今天上午，A股市场再现惊人一幕。此前连续7天跌停的东方集团，今天早上亦一度跌停，但随后被快速拉起封死涨 停，股价实现地天板，涨停板封单达到了惊人的158万手。 中国证监会于 2025年2月28日通报了东方集团财务造假案阶段性调查进展情况，现已初步查明，东方集团披露 的 2020 年至 2023年财务信息严重不实，涉嫌重大财务造假。上述查明事实显示，公司预计将触及《上海证券交易 所股票上市规则》规定的连续多年财务造假等重大违法强制退市情形。随后，公司股价连续跌停。 去年6月20日，因涉嫌信息披露违法违规，根据相关法律法规，证监会对东方集团立案。随后东方集团多次发布关于 立案调查进展暨风险提示公告，其中指出，若后续经证监会行政处罚认定的事实，触及《上海证 ...